Abstract
This is the latest RNAi-based Therapeutics Market Report from Select Biosciences. This report presents an up-to-date thorough analysis of the RNAi therapeutics landscape based upon our continuing coverage of this dynamic marketplace. This report presents an exhaustive analysis of all the therapeutics areas where research efforts using RNAi-based therapeutics are being focused: From Research/Pre-Clinical through Phase III Clinical Trials. Select Biosciences proprietary market survey addresses druggability trends, drug target classes (where RNAi therapeutics will impact) and different therapeutic areas in terms of challenges/opportunities/quantitative industry metrics-this highly valuable dataset is based on an extensive market analysis.
An extensive analysis of the Intellectual Property (IP) landscape in RNAi therapeutics space, RNAi technology trends, and relevant company profiles make this report a complete and timely industry analysis.
Topics Covered in this Report
- Opportunities and challenges in the RNAi therapeutics space
- Therapeutics areas impacted by RNAi therapeutics: Timeline for impact, top-most challenge in each therapeutic area
- Different target classes and their amenability to targeting using RNAi therapeutics
- Top-most drug target class for RNAi therapeutics
- Delivery approach by therapeutic area
- Factors that determine whether a given target will be druggable via RNAi-based therapeutics
- Opportunities for vendors in the space
- Research/Pre-Clinical, Phase I, Phase II, and Phase III RNAi therapeutics Clinical Trials: Details by company, molecular target, therapeutic/disease area, partnership[s]
- Technology trends in the RNAi space
- Intellectual property (IP) in the RNAi therapeutics space: Landscape and discussion of the various key patents
- Relevant company profiles: Partnerships, therapeutics/trials pipeline
Table of Contents
Chapter I. Executive Summary
Chapter II. Opportunities and Challenges In the Space
Chapter III. RNAi Therapeutics Market Analysis: Results of Market Survey performed by Select Biosciences to Analyze the Market Landscape
- Geographic Distribution of the Respondent Pool
- Affiliation of the Respondent Pool
- Challenges Impacting RNAi Therapeutics by Therapeutic/ Disease Area
- Top-Most Challenge by Therapeutic/ Disease Area
- Timeline of Impact by Therapeutic Area
- Delivery Approach by Therapeutic Area
- Drug Target Classes amenable to RNAi Therapeutics
- Druggability Factors
- Factors that determine whether a given drug target will be druggable via RNAi-based therapeutics
- Key Challenges for RNAi-based therapeutics
- Opportunities in the RNAi-based Therapeutics marketplace -- [ie., what products/ services would be of value to the industry]
Chapter IV. RNAi Therapeutics in Development
- Cancer
- Cardiac Disease
- Immunologic Disease
- Infectious Disease
- Inflammation
- Lifestyle
- Metabolic Disease
- Neurologic Disease
- Opthalmic Disease
- Renal Disease
- Respiratory Disease
Appendix I. Research Methodology
Appendix II. Technology Trends in the RNA Interference (RNAi) Space
- Scope
- End-user Segmentation
- Technologies for Inducing RNAi
- Methods for Detecting Gene Silencing
- Libraries of siRNAs/ shRNAs to Knock-down Genes en masse
- Publicly-Available Large-scale Mammalian RNAi Libraries
- The RNAi Consortium (TRC): A Cooperative Effort to
- Generate Large Libraries for Gene Knockdown
- Comparison of Strategies for Target Validation, Especially in the Pharmaceutical Industry
- Market Shifts in the RNAi Space: Where is the Field Heading?
- MicroRNA-based RNAi Interference: The Leading-Edge of the RNAi Space
- Biological Function of microRNAs
- Role of MicroRNAs in Cancer
- MicroRNAs in Human Cancer: The Different Molecular Entities Identified and the Conflicting Experimental Evidence Thus Far
- SWOT Analysis of the Various Technologies in the RNAi Space, and Vendors Commercializing These Technologies
Appendix III. Intellectual Property [IP] in the RNAi Therapeutics Space
- Timeline
- Key Founding IP
- RNAi Patent Landscape and key claims in major patents
- RNAi Therapeutics IP Landscape-2D Maps of the Space, annotated with patent filings for some of the key companies in the RNAi therapeutics space
Appendix IV. Relevant Company Profiles
- Alnylam Pharmaceuticals, Inc.
- Benitec Ltd.
- Calando Pharma
- Intradigm
- Nastech Pharmaceutical Company, Inc.
- Nucleonics, Inc.
- Opko Corporation
- Quark Biotech
- RXi Pharmaceuticals
- Santaris Pharma A/ S
- Silence Therapeutics AG
